Is Buying 52-Week Stock Like LeMaitre Vascular Inc (LMAT) a Winning Strategy?

September 17, 2017 - By Winifred Garcia

Investors sentiment decreased to 1.12 in Q4 2016. Its down 0.44, from 1.56 in 2016Q3. It turned negative, as 11 investors sold LeMaitre Vascular Inc shares while 39 reduced holdings. 18 funds opened positions while 38 raised stakes. 10.81 million shares or 0.20% more from 10.78 million shares in 2016Q3 were reported.
Morgan Stanley reported 174,023 shares. Goldman Sachs Gp holds 0% or 13,667 shares. 13,592 were accumulated by Citigroup Inc. Geneva Advisors Ltd Limited Liability Company holds 0% of its portfolio in LeMaitre Vascular Inc (NASDAQ:LMAT) for 9,115 shares. 436,046 were reported by Blackrock Fund Advsr. Federated Investors Pa reported 157,423 shares. Numeric Limited Co has invested 0.01% in LeMaitre Vascular Inc (NASDAQ:LMAT). Sei Invests accumulated 3,327 shares. 95,310 are owned by Prudential. Legal & General Pcl holds 0% of its portfolio in LeMaitre Vascular Inc (NASDAQ:LMAT) for 3,584 shares. Manufacturers Life Insurance Communication The reported 9,217 shares stake. State Street Corp invested in 329,877 shares or 0% of the stock. Sheets Smith Wealth Mngmt invested in 0.17% or 23,522 shares. Globeflex Capital Limited Partnership holds 0.58% in LeMaitre Vascular Inc (NASDAQ:LMAT) or 91,477 shares. Greenleaf Tru invested in 14,738 shares.

Since May 2, 2017, it had 0 insider purchases, and 7 sales for $8.57 million activity. 2,346 shares valued at $73,717 were sold by Wijas Michael T on Thursday, June 1. Roberts David B sold $1.38M worth of stock. Kamke Trent G sold $477,822 worth of stock or 15,780 shares.

The stock of LeMaitre Vascular Inc (NASDAQ:LMAT) hit a new 52-week high and has $41.67 target or 8.00 % above today’s $38.58 share price. The 6 months bullish chart indicates low risk for the $733.91M company. The 1-year high was reported on Sep, 17 by Barchart.com. If the $41.67 price target is reached, the company will be worth $58.71 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock increased 1.29% or $0.49 on September 15, reaching $38.58. About 655,848 shares traded or 206.91% up from the average. LeMaitre Vascular Inc (NASDAQ:LMAT) has risen 101.07% since September 17, 2016 and is uptrending. It has outperformed by 84.37% the S&P500.

Analysts expect LeMaitre Vascular Inc (NASDAQ:LMAT) to report $0.20 EPS on October, 25.They anticipate $0.03 EPS change or 17.65 % from last quarter’s $0.17 EPS. LMAT’s profit would be $3.80 million giving it 48.23 P/E if the $0.20 EPS is correct. After having $0.23 EPS previously, LeMaitre Vascular Inc’s analysts see -13.04 % EPS growth.

LeMaitre Vascular Inc (NASDAQ:LMAT) Ratings Coverage

Among 11 analysts covering LeMaitre Vascular (NASDAQ:LMAT), 7 have Buy rating, 0 Sell and 4 Hold. Therefore 64% are positive. LeMaitre Vascular had 30 analyst reports since July 29, 2015 according to SRatingsIntel. As per Friday, July 28, the company rating was maintained by Stifel Nicolaus. The stock of LeMaitre Vascular Inc (NASDAQ:LMAT) has “Mkt Perform” rating given on Wednesday, February 22 by Barrington Research. As per Wednesday, July 29, the company rating was maintained by Benchmark. As per Monday, July 10, the company rating was downgraded by Benchmark. On Monday, July 10 the stock rating was downgraded by Canaccord Genuity to “Hold”. The stock has “Buy” rating by Roth Capital on Tuesday, May 3. The firm has “Buy” rating given on Friday, July 28 by Roth Capital. The rating was maintained by Roth Capital with “Buy” on Monday, December 7. The stock has “Neutral” rating by Sidoti on Wednesday, January 20. The stock has “Buy” rating by Dougherty & Company on Monday, December 7.

More notable recent LeMaitre Vascular Inc (NASDAQ:LMAT) news were published by: Globenewswire.com which released: “LeMaitre Vascular to Present at Upcoming Investor Conferences” on July 25, 2017, also Seekingalpha.com with their article: “LeMaitre Vascular’s (LMAT) CEO George LeMaitre on Q2 2017 Results – Earnings …” published on July 28, 2017, Seekingalpha.com published: “LeMaitre Vascular’s (LMAT) CEO George LeMaitre on Q1 2017 Results – Earnings …” on April 27, 2017. More interesting news about LeMaitre Vascular Inc (NASDAQ:LMAT) were released by: Nasdaq.com and their article: “Why LeMaitre Vascular (LMAT) Could Be Positioned for a Surge” published on August 21, 2017 as well as Seekingalpha.com‘s news article titled: “LeMaitre Vascular Is A Wonderful Business At A Fair Price” with publication date: December 15, 2016.

LeMaitre Vascular, Inc. is a provider of medical devices for the treatment of peripheral vascular disease. The company has market cap of $733.91 million. The Firm develops, makes and markets medical devices and implants used primarily in the field of vascular surgery. It has a 55.5 P/E ratio. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.